Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma
Cristiane Arruda Dalla‐Torre(Support group for adolescents and children with cancer), Jeremy A. Squire(Universidade de São Paulo), Susan Chilton‐MacNeill(Hospital for Sick Children), Antônio Sérgio Petrilli(Support group for adolescents and children with cancer), Maisa Yoshimoto(University of Alberta), Anthony M. Joshua(St Vincent's Hospital Sydney), Maria Zieleńska(University of Toronto), Silvia RC de Toledo(Support group for adolescents and children with cancer), Joyce Andrade(Universidade Federal de São Paulo), Chung-Hae Lee(Ontario Institute for Cancer Research)
Cited by 131
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869